Uric acid (UA) is the final product of the catabolism of endogenous and exogenous purine nucleotides. While its association with articular gout and kidney disease has been known for a long time, new data have demonstrated that UA is also related to cardiovascular (CV) diseases. UA has been identified as a significant determinant of many different outcomes, such as all-cause and CV mortality, and also of CV events (mainly Acute Coronary Syndromes (ACS) and even strokes). Furthermore, UA has been related to the development of Heart Failure, and to a higher mortality in decompensated patients, as well as to the onset of atrial fibrillation. After a brief introduction on the general role of UA in CV disorders, this review will be focused on UA’s relationship with CV outcomes, as well as on the specific features of patients with ACS and Chronic Coronary Syndrome. Finally, two issues which remain open will be discussed: the first is about the identification of a CV UA cut-off value, while the second concerns the possibility that the pharmacological reduction of UA is able to lower the incidence of CV events.

Maloberti, A., Biolcati, M., Ruzzenenti, G., Giani, V., Leidi, F., Monticelli, M., et al. (2021). The role of uric acid in acute and chronic coronary syndromes. JOURNAL OF CLINICAL MEDICINE, 10(20) [10.3390/jcm10204750].

The role of uric acid in acute and chronic coronary syndromes

Maloberti A.
;
Nava S.;Soriano F.;Oliva F.;Giannattasio C.
2021

Abstract

Uric acid (UA) is the final product of the catabolism of endogenous and exogenous purine nucleotides. While its association with articular gout and kidney disease has been known for a long time, new data have demonstrated that UA is also related to cardiovascular (CV) diseases. UA has been identified as a significant determinant of many different outcomes, such as all-cause and CV mortality, and also of CV events (mainly Acute Coronary Syndromes (ACS) and even strokes). Furthermore, UA has been related to the development of Heart Failure, and to a higher mortality in decompensated patients, as well as to the onset of atrial fibrillation. After a brief introduction on the general role of UA in CV disorders, this review will be focused on UA’s relationship with CV outcomes, as well as on the specific features of patients with ACS and Chronic Coronary Syndrome. Finally, two issues which remain open will be discussed: the first is about the identification of a CV UA cut-off value, while the second concerns the possibility that the pharmacological reduction of UA is able to lower the incidence of CV events.
Articolo in rivista - Review Essay
Acute coronary syndrome; Chronic coronary syndrome; Uric acid
English
16-ott-2021
2021
10
20
4750
open
Maloberti, A., Biolcati, M., Ruzzenenti, G., Giani, V., Leidi, F., Monticelli, M., et al. (2021). The role of uric acid in acute and chronic coronary syndromes. JOURNAL OF CLINICAL MEDICINE, 10(20) [10.3390/jcm10204750].
File in questo prodotto:
File Dimensione Formato  
10281-332310_VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 908.13 kB
Formato Adobe PDF
908.13 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/332310
Citazioni
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 33
Social impact